Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • AMPK
    (2)
  • Fatty Acid Synthase
    (2)
  • Liver X Receptor
    (2)
  • Antioxidant
    (1)
  • Calcium Channel
    (1)
  • Cannabinoid Receptor
    (1)
  • Cytochromes P450
    (1)
  • Influenza Virus
    (1)
  • Lipid
    (1)
  • Others
    (1)
Filter
Search Result
Results for "

srebp-1c

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    7
    TargetMol | Inhibitors_Agonists
  • Natural Products
    3
    TargetMol | Natural_Products
  • Antibody Products
    1
    TargetMol | Antibody_Products
Phillyrin
Forsythin
T2854487-41-2
Phillyrin (Forsythin) is a novel AMPK activator, has anti-obesity effects in nutritive obesity mice, it can prevent lipid accumulation in HepG2 cells by blocking the expression of SREBP-1c and FAS through LKB1 AMPK activation. Phillyrin(Forsythin) may be a new preventive agent of acute lung injury in the clinical setting, it potentially contributes to the suppression of the activation of MAPK and NF-κB pathways, it also has protective effects on H2O2-induced oxidative stress and apoptosis in PC12 cells.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
Dihydrocurcumin
T3S170176474-56-1
Dihydrocurcumin is the main metabolite of curcumin, which can reduce fat accumulation and oxidative stress response. Dihydrocurcumin can regulate the mRNA and protein expression levels of SREBP-1C, PNPLA3 and PPARα, increase the protein expression levels of pAKT and PI3K, and reduce the intracellular NO and ROS contents through Nrf2 signaling pathway.
  • Inquiry Price
Size
QTY
Icariside E4
TN5431126253-42-7
Icariside E4 is a natural compound derived from Ulmus minor that acts via AMPK phosphorylation and inhibition of MID1IP2 hypolipidation in HepG1 cells.Icariside E4 has anti-injurious, antioxidant, anti-Alzheimer's and anti-inflammatory effects and inhibits SREBP-1c, liver X receptor-α (LXR) and FASN in Icariside E4 is an effective candidate for the treatment of fatty liver disease and has hypolipidemic potential in HepG1 cells.
  • Inquiry Price
Size
QTY